PT3609497T - Niraparib, acetato de abiraterona e prednisona para o tratamento do cancro da próstata - Google Patents

Niraparib, acetato de abiraterona e prednisona para o tratamento do cancro da próstata

Info

Publication number
PT3609497T
PT3609497T PT187208954T PT18720895T PT3609497T PT 3609497 T PT3609497 T PT 3609497T PT 187208954 T PT187208954 T PT 187208954T PT 18720895 T PT18720895 T PT 18720895T PT 3609497 T PT3609497 T PT 3609497T
Authority
PT
Portugal
Prior art keywords
niraparib
prednisone
treatment
prostate cancer
abiraterone acetate
Prior art date
Application number
PT187208954T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3609497(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT3609497T publication Critical patent/PT3609497T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PT187208954T 2017-04-13 2018-04-09 Niraparib, acetato de abiraterona e prednisona para o tratamento do cancro da próstata PT3609497T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13

Publications (1)

Publication Number Publication Date
PT3609497T true PT3609497T (pt) 2023-01-23

Family

ID=62067858

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187208954T PT3609497T (pt) 2017-04-13 2018-04-09 Niraparib, acetato de abiraterona e prednisona para o tratamento do cancro da próstata

Country Status (33)

Country Link
US (4) US20180296574A1 (enExample)
EP (3) EP4176879A1 (enExample)
JP (3) JP7141408B2 (enExample)
KR (2) KR20190134718A (enExample)
CN (2) CN119235874A (enExample)
AU (2) AU2018251594A1 (enExample)
CA (1) CA3059562A1 (enExample)
CL (1) CL2019002871A1 (enExample)
CO (1) CO2019011591A2 (enExample)
CR (1) CR20190467A (enExample)
DK (1) DK3609497T3 (enExample)
DO (1) DOP2019000264A (enExample)
EA (1) EA201992430A1 (enExample)
ES (1) ES2931052T3 (enExample)
HR (1) HRP20221327T1 (enExample)
HU (1) HUE060460T2 (enExample)
IL (2) IL269879B2 (enExample)
JO (2) JOP20190244B1 (enExample)
LT (1) LT3609497T (enExample)
MA (1) MA48728B1 (enExample)
MD (1) MD3609497T2 (enExample)
MX (2) MX2019012296A (enExample)
MY (1) MY209010A (enExample)
NI (1) NI201900105A (enExample)
PE (1) PE20200444A1 (enExample)
PH (1) PH12019502317A1 (enExample)
PL (1) PL3609497T3 (enExample)
PT (1) PT3609497T (enExample)
RS (1) RS63832B1 (enExample)
SG (1) SG11201909552VA (enExample)
SM (1) SMT202200467T1 (enExample)
UA (1) UA129514C2 (enExample)
WO (1) WO2018191141A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119606965A (zh) 2016-07-29 2025-03-14 詹森药业有限公司 治疗前列腺癌的方法
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
AU2021269115A1 (en) * 2020-05-08 2023-01-19 Janssen Pharmaceutica Nv Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
KR20230159510A (ko) * 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
TWI828471B (zh) 2021-12-15 2024-01-01 大陸商湖南慧澤生物醫藥科技有限公司 醋酸阿比特龍的自微乳組合物和應用
CN118973555A (zh) * 2022-04-07 2024-11-15 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
WO2025027138A1 (en) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
PL2061561T3 (pl) * 2006-08-25 2013-12-31 Janssen Oncology Inc Kompozycje do leczenia raka
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
CL2019002871A1 (es) 2019-12-27
ES2931052T3 (es) 2022-12-23
SG11201909552VA (en) 2019-11-28
MY209010A (en) 2025-06-16
US20240245710A1 (en) 2024-07-25
LT3609497T (lt) 2022-12-12
DOP2019000264A (es) 2020-07-15
EA201992430A1 (ru) 2020-02-28
KR20190134718A (ko) 2019-12-04
PE20200444A1 (es) 2020-02-28
EP4176879A1 (en) 2023-05-10
JP2022141881A (ja) 2022-09-29
MA48728B1 (fr) 2022-10-31
JP2024023344A (ja) 2024-02-21
EP3609497A1 (en) 2020-02-19
WO2018191141A1 (en) 2018-10-18
CA3059562A1 (en) 2018-10-18
BR112019021466A2 (pt) 2020-05-12
EP3609497B1 (en) 2022-10-12
US20180296574A1 (en) 2018-10-18
IL269879A (enExample) 2019-11-28
MX2019012296A (es) 2019-11-28
IL269879B2 (en) 2025-10-01
RS63832B1 (sr) 2023-01-31
MD3609497T2 (ro) 2023-03-31
HRP20221327T1 (hr) 2023-03-17
US20240398837A1 (en) 2024-12-05
JP2020516646A (ja) 2020-06-11
JP7141408B2 (ja) 2022-09-22
AU2024202346A1 (en) 2024-05-02
NI201900105A (es) 2020-03-11
MA48728A (fr) 2020-04-08
CN119235874A (zh) 2025-01-03
CN110753545A (zh) 2020-02-04
KR20260048358A (ko) 2026-04-09
JP7407880B2 (ja) 2024-01-04
SMT202200467T1 (it) 2023-01-13
MX2023009569A (es) 2023-08-22
JOP20230159A1 (ar) 2023-07-13
AU2018251594A1 (en) 2019-10-24
JOP20190244A1 (ar) 2019-10-13
AU2024202346B2 (en) 2026-01-22
CO2019011591A2 (es) 2020-02-28
US20220175801A1 (en) 2022-06-09
JOP20190244B1 (ar) 2024-04-18
IL269879B1 (en) 2025-06-01
PL3609497T3 (pl) 2023-01-23
EP4176878A1 (en) 2023-05-10
UA129514C2 (uk) 2025-05-21
PH12019502317A1 (en) 2020-07-06
HUE060460T2 (hu) 2023-03-28
IL320452A (en) 2025-06-01
CR20190467A (es) 2020-03-09
DK3609497T3 (da) 2022-10-31

Similar Documents

Publication Publication Date Title
IL271888A (en) Therapeutic and diagnostic methods for cancer
IL274246A (en) Methods for diagnosing and treating cancer
HUE060460T2 (hu) Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL269150A (en) Compositions and methods for treating cancer
IL268814A (en) Compositions and methods for treatment of cancer
EP3581182A4 (en) DRUG COMBINATION FOR THE TREATMENT OF PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
IL258955A (en) Compositions and methods for treatment of cancer
IL273071A (en) Treatment and diagnosis methods for cancer
IL261422A (en) Therapeutic and diagnostic methods for cancer
IL253701B (en) Medicinal material for bile duct cancer
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
EP3723772A4 (en) COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR THE TREATMENT OF CANCER AND METABOLIC INTERVENTION THERAPY
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
IL262208A (en) Diagnostic and therapeutic methods for cancer
IL269157A (en) Compositions and methods for treating cancer
HK1221424A1 (zh) 治疗癌症的药物组合
IL264443A (en) Methods of treating prostate cancer
IL265697B1 (en) Treatment of prostate cancer
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
IL268163A (en) Methods, compositions, and kits for treatment of cancer
IL274008A (en) Anti-MSLN antibody and a pharmaceutical preparation containing it for the treatment of cancer
IL281281A (en) Combination therapy for the treatment of prostate cancer
IL272147A (en) Methods and compositions for the treatment of cancer
IL269769B (en) Compounds, composition and uses thereof for treating cancer